Dr Reddy's launches first cut-price biosimilar darbepoetin alfa
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories has launched the first cut-price biosimilar darbepoetin alfa on the Indian market. The product, sold as Cresp, has been approved in India for the treatment of anaemia due to chronic kidney disease and anaemia due to chemotherapy.